Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets
dc.creator | Ghanaatian N. | |
dc.creator | Lashgari N.-A. | |
dc.creator | Abdolghaffari A.H. | |
dc.creator | Rajaee S.M. | |
dc.creator | Panahi Y. | |
dc.creator | Barreto G.E. | |
dc.creator | Butler A.E. | |
dc.creator | Sahebkar A. | |
dc.date.accessioned | 2020-09-02T22:19:21Z | |
dc.date.accessioned | 2022-11-08T20:18:55Z | |
dc.date.available | 2020-09-02T22:19:21Z | |
dc.date.available | 2022-11-08T20:18:55Z | |
dc.date.created | 2020-09-02T22:19:21Z | |
dc.date.issued | 2019 | |
dc.identifier | 234, 8, 12237-12248 | |
dc.identifier | 00219541 | |
dc.identifier | https://hdl.handle.net/20.500.12728/4715 | |
dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/5142944 | |
dc.language | en | |
dc.publisher | Wiley-Liss Inc. | |
dc.subject | curcumin | |
dc.subject | immune system | |
dc.subject | inflammation | |
dc.subject | multiple sclerosis (MS) | |
dc.subject | curcumin | |
dc.subject | interleukin 1 | |
dc.subject | interleukin 17 | |
dc.subject | interleukin 22 | |
dc.subject | interleukin 6 | |
dc.subject | interleukin 8 | |
dc.subject | macrophage inflammatory protein 2 | |
dc.subject | antiinflammatory agent | |
dc.subject | curcumin | |
dc.subject | cytokine | |
dc.subject | plant extract | |
dc.subject | turmeric extract | |
dc.subject | antiinflammatory activity | |
dc.subject | blood brain barrier | |
dc.subject | calcium cell level | |
dc.subject | CD4+ T lymphocyte | |
dc.subject | cell adhesion | |
dc.subject | cell differentiation | |
dc.subject | cell migration | |
dc.subject | Curcuma longa | |
dc.subject | cytokine production | |
dc.subject | drug bioavailability | |
dc.subject | drug delivery system | |
dc.subject | drug mechanism | |
dc.subject | drug metabolism | |
dc.subject | human | |
dc.subject | immune response | |
dc.subject | immunocompetent cell | |
dc.subject | in vitro study | |
dc.subject | in vivo study | |
dc.subject | microemulsion | |
dc.subject | microencapsulation | |
dc.subject | multiple sclerosis | |
dc.subject | nerve fiber degeneration | |
dc.subject | nonhuman | |
dc.subject | polymerization | |
dc.subject | prevalence | |
dc.subject | priority journal | |
dc.subject | regulatory T lymphocyte | |
dc.subject | Review | |
dc.subject | Th17 cell | |
dc.subject | tight junction | |
dc.subject | animal | |
dc.subject | chemistry | |
dc.subject | Curcuma | |
dc.subject | inflammation | |
dc.subject | metabolism | |
dc.subject | multiple sclerosis | |
dc.subject | Animals | |
dc.subject | Anti-Inflammatory Agents | |
dc.subject | Curcuma | |
dc.subject | Curcumin | |
dc.subject | Cytokines | |
dc.subject | Humans | |
dc.subject | Inflammation | |
dc.subject | Multiple Sclerosis | |
dc.subject | Plant Extracts | |
dc.title | Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets | |
dc.type | Review |